Seroepidemiological study of the prevalence of SARS-CoV-2 antibodies (IgG and IgM) positive titers in the population, referring to the laboratories of Urmia city

Ansari, Mohammad Hassan; Saadatian kharajo, Ramin; Jalali, Ladan; Khalkhali, Hamid Reza; Rasmi, Yousf

doi:10.61186/rabms.10.4.400

Volume 10, Issue 4 (11-2024) Journal of Research in Applied and Basic Medical Sciences 2024, 10(4): 400-409 | Back to browse issues page

‎ 10.61186/rabms.10.4.400

Mendeley

Zotero

RefWorks

Ansari M H, Saadatian kharajo R, Jalali L, Khalkhali H R, Rasmi Y. Seroepidemiological study of the prevalence of SARS-CoV-2 antibodies (IgG and IgM) positive titers in the population, referring to the laboratories of Urmia city. Journal of Research in Applied and Basic Medical Sciences 2024; 10 (4) :400-409
URL: http://ijrabms.umsu.ac.ir/article-1-341-en.html

Seroepidemiological study of the prevalence of SARS-CoV-2 antibodies (IgG and IgM) positive titers in the population, referring to the laboratories of Urmia city

Mohammad Hassan Ansari

, Ramin Saadatian kharajo

, Ladan Jalali ^*

, Hamid Reza Khalkhali

, Yousf Rasmi

Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , jalalyl@yahoo.com

Abstract: (305 Views)

Background & Aims: COVID-19 is one of the most significant diseases of recent years, spreading globally through human-to-human transmission. The purpose of this study is to investigate the seroepidemiological titers of SARS-CoV-2 antibodies in the urban population of Urmia city based on samples from individuals who referred to local laboratories. This study aims to provide new insights into the epidemiologic behavior of COVID-19 in society.
Materials & Methods: Approximately 4,000 people who referred to the laboratories of Urmia participated in this study. Plasma levels of IgM and IgG antibodies were measured, and the frequency of positive antibody titers in the entire population was calculated based on demographic characteristics such as age and gender. IgM and IgG levels were compared between the two genders. Additionally, IgM and IgG levels were compared across age groups: children and adolescents under 20 years old; young adults (20–40 years old); middle-aged individuals (40-60 years old); and the elderly (60 years and older).
Results: In this study, the frequencies of IgM+ and IgG+ were determined as well as the frequency of (IgM/IgG+) among the participants. Plasma levels of IgG were not different between women and men, whereas IgM levels were higher in women than in men. The plasma levels of antibodies in the age groups of children and young people were lower than in the middle-aged and elderly age groups.
Conclusion: The findings of this study highlight that older adults and individuals with confirmed infections mounted a stronger antibody response. Additionally, the differences in IgM levels between genders warrant further research to explore their potential clinical significance.

Keywords: COVID19, IgG antibody, IgM antibody, SARS-CoV2, seroepidemiology

Full-Text [PDF 482 kb] (108 Downloads)

Type of Study: orginal article | Subject: General

References

1. Britannica E. Leaf-nosed bat. Encyclopædia Britannica Online. 2009. [URL]

2. Saadat S, Rawtani D, Hussain CM. Environmental perspective of COVID-19. Sci. Total Environ 2020;728(138870):138870. [DOI:10.1016/j.scitotenv.2020.138870] [PMID] [PMCID]

3. Manam A, Chennath A, Sinha Y, Arya A. Clinical Manifestations and complications of COVID-19. Praxis Undergraduate Medical Research Journal. 2020;3(SPECIAL).

4. Ramatillah DL, Gan SH, Pratiwy I, Syed Sulaiman SA, Jaber AAS, Jusnita N, et al. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. PLoS One 2022;17(1):e0262438. [DOI:10.1371/journal.pone.0262438] [PMID] [PMCID]

5. Romero-Gameros CA, Colin-Martínez T, Waizel-Haiat S, Vargas-Ortega G, Ferat-Osorio E, Guerrero-Paz JA, et al. Diagnostic accuracy of symptoms as a diagnostic tool for SARS-CoV 2 infection: a cross-sectional study in a cohort of 2,173 patients. BMC Infect. Dis 2021;21(1):255. [DOI:10.1186/s12879-021-05930-1] [PMID] [PMCID]

6. Khatami F, Saatchi M, Zadeh SST, Aghamir ZS, Shabestari AN, Reis LO, et al. A meta-analysis of accuracy and sensitivity of chest CT and RT-PCR in COVID-19 diagnosis. Sci. Rep 2020;10(1):22402. [DOI:10.1038/s41598-020-80061-2] [PMID] [PMCID]

7. Lim J, Lee J. Current laboratory diagnosis of coronavirus disease 2019. Korean J. Intern. Med 2020;35(4):741-8. [DOI:10.3904/kjim.2020.257] [PMID] [PMCID]

8. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: A systematic review. PLoS One 2020;15(12):e0242958. [DOI:10.1371/journal.pone.0242958] [PMID] [PMCID]

9. Tapia-Sidas DA, Vargas-Hernández BY, Ramírez-Pool JA, Núñez-Muñoz LA, Calderón-Pérez B, González-González R, et al. Starting from scratch: Step-by-step development of diagnostic tests for SARS-CoV-2 detection by RT-LAMP. PLoS One 2023;18(1):e0279681. [DOI:10.1371/journal.pone.0279681] [PMID] [PMCID]

10. Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, et al. Challenges in laboratory diagnosis of the novel Coronavirus SARS-CoV-2. Viruses 2020;12(6):582. [DOI:10.3390/v12060582] [PMID] [PMCID]

11. Lou B, Li T-D, Zheng S-F, Su Y-Y, Li Z-Y, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur. Respir. J 2020;56(2):2000763. [DOI:10.1183/13993003.00763-2020] [PMID] [PMCID]

12. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M-C, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75(7):1564-81. [DOI:10.1111/all.14364] [PMID] [PMCID]

13. Al-Ibraheemi JSS, Al-Saeedi A-S. The relationship between IgG and IgM levels and severity of symptoms in COVID-19 patients confirmed by rapid antigen test. J. Med. Life 2021;14(6):790-6. [DOI:10.25122/jml-2021-0194] [PMID] [PMCID]

14. Jia X, Zhang P, Tian Y, Wang J, Zeng H, Wang J, et al. Clinical significance of an IgM and IgG test for diagnosis of highly suspected COVID-19. Front. Med. (Lausanne) 2021;8:569266. [DOI:10.3389/fmed.2021.569266] [PMID] [PMCID]

15. Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, et al. The dynamic changes of serum IgM and IgG against SARS‐CoV‐2 in patients with COVID‐19. Journal of medical virology. 2021;93(2):924-33. [DOI:10.1002/jmv.26353] [PMID] [PMCID]

16. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell. Mol. Immunol 2020;17(7):773-5. [DOI:10.1038/s41423-020-0474-z] [PMID] [PMCID]

17. McIntosh K, Kapikian AZ, Turner HC, Hartley JW, Parrott RH, Chanock RM. Seroepidemiologic studies of coronavirus infection in adults and children. Am. J. Epidemiol 1970;91(6):585-92. [DOI:10.1093/oxfordjournals.aje.a121171] [PMID] [PMCID]

18. Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, et al. The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study. Trans. R. Soc. Trop. Med. Hyg 2022;116(3):242-51. [DOI:10.1093/trstmh/trab109] [PMID]

19. Vallinoto ACR, da Silva Torres MK, Vallinoto MC, Cayres Vallinoto IMV. The challenges of COVID-19 in the Brazilian Amazonian communities and the importance of seroepidemiological surveillance studies. Int. J. Equity Health 2020;19(1):140. [DOI:10.1186/s12939-020-01256-7] [PMID] [PMCID]

20. Friedler A. Sociocultural, behavioural and political factors shaping the COVID-19 pandemic: the need for a biocultural approach to understanding pandemics and (re)emerging pathogens. Glob. Public Health 2021;16(1):17-35. Available from: [DOI:10.1080/17441692.2020.1828982] [PMID]

21. Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: A global challenge with old history, epidemiology and progress so far. Molecules 2020;26(1):39. [DOI:10.3390/molecules26010039] [PMID] [PMCID]

22. Elliott P, Peakman TC, UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol 2008;37(2):234-44. [DOI:10.1093/ije/dym276] [PMID]

23. Mirjalili MR, Namayandeh SM, Lotfi MH, Dehghani MR, Mirzaei M, Talebi AR, et al. COVID-19 seroepidemiology study of Yazd Province, first peak, spring 2020: A population-based cross-sectional study. JSSU 2021; [DOI:10.18502/ssu.v28i12.5780]

24. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin. Microbiol. Infect 2021;27(3):331-40. [DOI:10.1016/j.cmi.2020.10.020] [PMID] [PMCID]

25. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396(10250):535-44. [DOI:10.1016/S0140-6736(20)31483-5] [PMID]

26. Metcalf CJE, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. The Lancet 2016;388(10045):728-30. [DOI:10.1016/S0140-6736(16)30164-7] [PMID]

27. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One 2020;15(12):e0244126. [DOI:10.1371/journal.pone.0244126] [PMID] [PMCID]

28. Moradi G, Mohamadi Bolbanabad A, Ahmadi S, Aghaei A, Bahrami F, Veysi A, et al. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study. Int. Immunopharmacol 2021;98(107893):107893. [DOI:10.1016/j.intimp.2021.107893] [PMID] [PMCID]

29. Zeng F, Wu M, Wang J, Li J, Hu G, Wang L. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients. J. Med. Virol 2021;93(12):6506-11. [DOI:10.1002/jmv.27152] [PMID] [PMCID]

30. Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P. Characteristics and mortality of hospitalized patients with COVID-19 in Iran: A national retrospective cohort study. Ann. Intern. Med 2021;174(1):125-7. [DOI:10.7326/M20-2911] [PMID] [PMCID]

31. Klein SL, Flanagan KL. Sex differences in immune responses. Nat. Rev. Immunol 2016;16(10):626-38. [DOI:10.1038/nri.2016.90] [PMID]

32. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009;10(5):509-16. [DOI:10.1038/gene.2009.12] [PMID] [PMCID]

33. Pradhan A, Olsson P-E. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol. Sex Differ 2020;11(1):53. [DOI:10.1186/s13293-020-00330-7] [PMID] [PMCID]

34. Megasari NLA, Utsumi T, Yamani LN, Juniastuti, Gunawan E, Furukawa K, et al. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. PLoS One 2021;16(5):e0251234. [DOI:10.1371/journal.pone.0251234] [PMID] [PMCID]

35. La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod. Biomed. Online 2020;41(3):483-99. [DOI:10.1016/j.rbmo.2020.06.001] [PMID] [PMCID]